Topical Clascoterone Evidence Revisited in 2026: Questions Teens With Inflammatory Acne Can Ask a Dermatologist

Topical clascoterone 1% cream (Winlevi) is an androgen-receptor inhibitor for acne in patients 12 and older, DailyMed states in the FDA label on DailyMed. For inflammatory acne, 2026 evidence supports asking a dermatologist about expected clearing, daily routine, irritation, combinations, and cost.

EMA describes clascoterone as competing with androgens such as dihydrotestosterone in oil glands and hair follicles to reduce oil and inflammation. Springer Dermatology and Therapy reported lower facial oil after 12 weeks in a 2025 interim analysis. That oil finding fits lesion improvements seen in earlier trials.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

How does it target inflamed breakouts?
How much clearing can teens expect?
Who might consider it under current guidance?
What safety topics deserve direct questions?
What should you ask at the visit?

How does it target inflamed breakouts?

EMA's Q&A explains the basic action in plain terms. Clascoterone competes with androgens including dihydrotestosterone for receptors in sebaceous glands and hair follicles. Less androgen signaling means less sebum and less inflammation.

Springer Dermatology and Therapy reported reduced facial sebum after 12 weeks of clascoterone 1% in a 2025 interim analysis. The authors linked that change to the drug's anti-androgen mechanism. For oily skin with tender bumps, that oil effect helps explain interest in a topical hormone-pathway option.

How much clearing can teens expect?

SkinTherapyLetter summarizes two identical 12-week trials in JAMA Dermatology SkinTherapyLetter summary of the trials. The trials enrolled 1,440 patients age 9 and older with moderate-to-severe facial acne. Treatment success reached 18.4% and 20.3% with clascoterone versus 9.0% and 6.5% with vehicle.

Both trials also showed significant inflammatory and noninflammatory lesion reductions. Most participants did not reach full treatment success by week 12. Ask what change in tender bumps would count as worthwhile for you.

Who might consider it under current guidance?

Medscape's summary of the American Academy of Dermatology 2024 guideline notes a conditional recommendation for patients 9 and older AAD guideline summary on Medscape. The guideline cites high certainty of benefit with case-by-case use partly over U.S. cost and access.

Conditional means the choice depends on values, coverage, and alternatives. DailyMed lists the FDA-approved use as 12 years and older. The trials studied moderate-to-severe facial acne in patients 9 and older. Ask whether your age, severity, and facial pattern match the studied group.

What safety topics deserve direct questions?

Sun Pharma safety information reports HPA-axis suppression at day 14 Winlevi safety information from Sun Pharma. Suppression occurred in 1 of 20 adults and 2 of 22 adolescents. All subjects returned to normal 4 weeks after stopping.

The same source notes teens may be more susceptible to systemic effects. DermNet, last reviewed July 2025, lists local irritation such as itching, redness, and peeling. The same review flags pregnancy and lactation data gaps.

What should you ask at the visit?

Bring a short list so nothing gets rushed. DermNet frames practical teen use around routine, tolerance, combinations, and coverage.

Write down current washes, treatments, and moisturizers before the visit. Bring pharmacy coverage details so the dermatologist can compare alternatives in one visit.

Twice-daily thin layer: can you keep it up for at least 12 weeks?
Irritation plan: what itching, redness, or peeling should trigger a call?
Combinations: can it pair with benzoyl peroxide or a retinoid?
Pregnancy and nursing: what data gaps apply to you?
Cost: what does insurance cover and what alternatives cost less?